The phrase "adverse deviations" is correct and usable in written English.
It can be used in contexts such as statistics, quality control, or risk management to refer to negative or undesirable variations from a standard or expected outcome.
Example: "The analysis revealed several adverse deviations from the projected sales figures, prompting a review of our marketing strategy."
Alternatives: "negative variations" or "unfavorable discrepancies".
An AE was defined as any adverse deviation from the patient's baseline condition during the trial.
An AE was defined as any adverse deviation from the patient's baseline condition during the trial (including laboratory abnormalities, intercurrent diseases and accidents), whether or not the change was considered to be related to the study drug.
Patients will be assessed for adverse events and protocol deviations in the perioperative period.
The attending veterinarian recorded details of all welfare matters, including protocol deviations, suspected adverse events, development of concurrent medical problems and euthanasia.
The DSMC's role is to provide scientific and ethical oversight by evaluating the following data provided to them on a semi-annual basis: participant recruitment, accrual, and retention; adverse events (AEs); protocol deviations; data monitoring; and participant characteristics.
In ADCT, 26 of 295 subjects (the epalrestat group, including six patients of major protocol deviations) reported adverse events (AEs; 8.8%); these occurred within the first year of treatment in 22 of the 26 subjects.
The SC met weekly via teleconference calls to review recruitment progress at each site, discuss and clarify questions sites might have regarding the implementation of the protocol, address clinical concerns with study participants, and report and discuss adverse events and protocol deviations (if any).
Four patients from the telbivudine arm discontinued treatment before the end of the 2-year study due to efficacy (achieved HBeAg seroconversion), and 10 patients from the lamivudine arm withdrew before the end of the 2-year study due to efficacy (n = 1) and protocol deviations or adverse events (n = 9).
A total of nine patients withdrew from the study (7 in the telbivudine arm and 2 in the lamivudine-switch arm) due to protocol deviations and/or adverse events.
CAP: Community acquired pneumonia; TEAEs: Treatment-emergent adverse events; SD: Standard deviation.
